#immunotherapy

Innovative CD40 Agonist Antibody Shows Systemic Cancer Reduction

A newly engineered CD40 agonist antibody, delivered via direct tumor injection, demonstrates potential for systemic cancer reduction in early trials, indicating significant implications for cancer treatment architecture.